8-K
filed May 9, 2024, 7:59 PM ET
ticker TBPH
CIK 0001583107
other
confidence high
sentiment neutral
materiality 0.10
Theravance Biopharma shareholders elect three Class I directors, ratify EY, approve say-on-pay
Theravance Biopharma, Inc.
- Elected Eran Broshy, James Kelly, Laurie Smaldone Alsup as Class I directors for three-year terms; votes for each exceeded 35 million.
- Ratified Ernst & Young as independent auditor for FY 2024 with 39,257,982 for, 228,078 against.
- Non-binding advisory resolution on named executive officer compensation passed with 35,205,714 for, 332,345 against.
- Total shares voted at annual meeting: 39,493,689 (81.3% of outstanding).
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Theravance Biopharma, Inc. shareholders approved Election of Class I directors: Eran Broshy, James Kelly, Laurie Smaldone Alsup at the 2024-05-08 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2024-05-08
Exact text from the filing
Proposal One – Based on the following results of voting, the nominees listed below were elected Class I directors to serve as members of the Board until the Company’s Annual General Meeting held in 2026 and until their successors are duly elected and qualified: Nominees For Against Abstain Broker Non- Votes Eran Broshy 35,316,310 223,797 635 3,952,947 James Kelly 35,265,676 274,631 435 3,952,947 Laurie Smaldone Alsup 35,290,841 240,365 9,536 3,952,947
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Theravance Biopharma, Inc. shareholders approved Non-binding advisory resolution regarding compensation of named executive officers at the 2024-05-08 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2024-05-08
Exact text from the filing
Proposal Three – Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company’s named executive officers was approved: For Against Abstain Broker Non- Votes Number of Shares Voted 35,205,714 332,345 2,683 3,952,947
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Theravance Biopharma, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-08 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2024-05-08
Exact text from the filing
Proposal Two – Based on the following results of voting, the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified: For Against Abstain Broker Non- Votes Number of Shares Voted 39,257,982 228,078 7,629 N/A
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.